Waverley Pharma Inc V.WAVE

Healthcare Biotechnology

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

TSXV:WAVE - Post by User

Waverley Pharma Inc > One year from now....estimate

<< Previous

Bullboard Posts

Next >>

Comment by NEMOMEIMPUNEon Feb 19, 2021 12:38pm

158 Views

Post# 32610554

RE:One year from now....estimate

Where to find the estimate for next year (they also say that the estimate is somewhat ruff and should be taken with some grains of salt).

First: https://wallmine.com/tsxv/wave
Then: third column (starting with "Range") go down three items, and you find
"1 year target".
There you see the presumed %target for next year. Clic that line and you will find some more info.
At the bottom is a range of companies with one year targets and presumed CAD/ share (compare the companies and you will find some good news).
Good hunting from Sweden
NEMO

<< Previous

Bullboard Posts

Next >>

BlackBerry partners with Avathon to enhance critical event management with AI